Deep mutational scans of XBB.1.5 and BQ.1.1 reveal ongoing epistatic drift during SARS-CoV-2 evolution

Author summary SARS-CoV-2 variants evolve in part via mutations in the spike receptor-binding domain (RBD) that impact the ability of this domain to evade binding by neutralizing antibodies while maintaining high-affinity binding to ACE2 receptor. To aid in ongoing viral forecasting and surveillance, we conducted high-throughput measurements of the impacts of all possible amino acid mutations or single-codon deletions on ACE2 binding in the newly evolved Omicron BQ.1.1 and XBB.1.5 variant backgrounds. We find that mutations and deletions are well-tolerated in these domains, consistent with the ongoing evolutionary potential of Omicron sub-variants. We show that the impacts of mutations on ACE2 binding continue to change over time due to the phenomenon of epistasis, though these shifts in mutational effect are less pronounced than epistatic shifts described in earlier variants of concern. Nonetheless, we show that this epistasis continues to enable SARS-CoV-2’s exploration of new mutational combinations as it evolves into new regions of sequence space, highlighting the ongoing evolutionary potential this virus will continue to exhibit.

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7

Author summary SARS-CoV-2 variants continue to emerge and circulate. Omicron sub-variants show severe evasion of the immune response induced by early-approved vaccines. Bivalent mRNA vaccines (prototype and Omicron BA. 5) have been approved for use in the United States and other countries. However, the co-circulation of SARS-CoV-2 variants (such as BA. 5.2, BF. 7, BQ. 1.1 and XBB) poses a challenge to disease control. The next-generation of COVID-19 vaccines need to induce potent and broad-spectrum immune responses. Here, we demonstrate a design strategy for trivalent SARS-CoV-2 vaccines with RBD-heterotrimers, which are single protein molecules without any linker sequences or trimerization domain. Biochemical and cryo-EM structural characterization demonstrated the total epitope exposure of RBD-trimers. Animal experiments showed that RBD-heterotrimers induce broad-spectrum protective immune responses. As a proof-of-concept, this trivalent immunogen design strategy is promising and practical for preventing the continuous circulation of SARS-CoV-2. This study provides guidance for future vaccine design against coronavirus and other viruses such as the influenza and dengue viruses.

Neutralising #immunity to #omicron sublineages #BQ11, #XBB, and #XBB15 in healthy #adults is boosted by bivalent #BA1-containing #mRNA #vaccination and previous Omicron infection, https://doi.org/10.1016/S1473-3099(23)00289-X
Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients - Nature Communications

Dewald et al. show a high Spike-IgG seroprevalence (95%) in a multicenter study with 1,411 participants. They determined a substantially reduced serum neutralization against the SARS-CoV-2 VOCs BA.4/5 and BQ.1.1. and explored predictive factors of neutralizing activity.

Nature
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies - Nature Communications

In this work, Planas et al. report that Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 escape neutralization from monoclonal antibodies, and sera from vaccinated individuals with or without Omicron BA.1/2 or BA.5 breakthrough infection.

Nature
#Japan, eight #covid19 wave: ''  According to the information released by the #Tokyo Metropolitan Welfare and #Health Bureau, starting from the 7th wave of the epidemic, the #omicron variant #BA5 is mainly prevalent in Japan, but it has been gradually replaced by the new mutant strains #BF7 and #BQ11 , #XBB15 replaced, their immune escape ability is stronger, and their transmission ability becomes stronger.'' SINA: https://k.sina.com.cn/article_5044281310_12ca99fde01901xx6l.html?from=news&subch=onews
日本新冠死亡人数飙升,第八波疫情为何突然凶险

日本新冠死亡人数飙升,第八波疫情为何突然凶险

#SARSCoV2 #BQ1 Sub variant family update 1/9

BQ.1 sub variant family continues to grow nationwide at 60% of recent cases with BQ.1.1 at 25%, BQ.1 at 10% and BQ.1.1.4 at 3%

#AK #OK #GA #OH #MN #NH #WV are seeing > 50% growth

#bq11